While a few studies have reported on undifferentiated carcinoma or rhabdoid tumors with SMARCA4 mutations in the gastrointestinal tract [21,22,23,24], the specific association between SMARCA4 mutations and clinicopathological factors or patient survival in GEA has not been fully elucidated. This evidence concerns the gene SMARCA4 and rhabdoid tumor.